Nathan Markward

Nathan Markward is principal research scientist for Avalere’s Health Economics and Advanced Analytics practice where he leads the conceptualization, execution, and delivery of comparative effectiveness, HEOR, performance improvement, and risk adjustment studies that drive opportunity identification and value creation for a diverse array of clients, including biopharmaceutical companies, device manufacturers, health plans, provider networks, patient advocacy groups, and medical societies.

Nathan is a seasoned quantitative scientist with more than 20 years of research, consulting, and management experience in academia, biotechnology, and healthcare. He has a strong background in real-world study design, theoretical and applied statistics, and the deployment of data mining tools, predictive models, and AI/machine learning algorithms in the context of health system operations, population health program evaluation, precision medicine product development, and value-based contracting.

Prior to joining Avalere, Nathan held advanced analytics leadership roles at Ochsner Health Network, RxAnte, UnitedHealth Group, Medco Health Solutions, and Express Scripts, as well as faculty and research appointments at Louisiana State University (LSU), Pennington Biomedical Research Center, Sirius Genomics, and Sequenom.

Nathan holds a BS in health planning and administration from the University of Illinois at Urbana-Champaign, an MPH in epidemiology from Tulane University, and a PhD in human genetics and measurement theory from LSU. He has also completed doctoral training in biostatistics, health policy, and epidemiology—molecular, psychiatric, and veterinary—at UIUC and the Johns Hopkins University, respectively, and a post-doctoral fellowship in statistical genetics at the Hayward Genetics Center.

Authored Content

A recent Avalere analysis of Medicare Fee-for-Service (FFS) data illustrates that treating major depressive disorder (MDD) in Medicare-eligible beneficiaries results in a 4% reduction in total cost compared to untreated patients, highlighting the importance of incentivizing adequate provider supply and payment in the geriatric psychiatry market.

An Avalere analysis determined that Medicare Fee-for-Service (FFS) patients who received personal care services experienced a decrease in Medicare expenditures over time when compared to a statistically comparable control group comprising patients who did not receive the same level of personalized care. The reduction in spend was specific to a subset of chronic conditions that were targeted operationally for intervention and case management.

Avalere’s data analytics and market access experts will be joined by Jeff Patton, MD and CEO of OneOncology, to explore critical issues and considerations for life sciences stakeholders following the pandemic.

Avalere research was published online in the Journal of Clinical Oncology Clinical Cancer Informatics, showing a considerable drop in cancer screening, diagnosis, and treatment for Medicare beneficiaries as a result of the ongoing COVID-19 pandemic.

Avalere analysis determined that Medicare Fee-for-Service (FFS) patients receiving home-based care services experienced a decrease in Medicare spending over time when compared to a statistically balanced, matched control group who do not appear to have received home care services. The spending differential was also found to be higher among Medicare beneficiaries with functional limitations and multiple chronic conditions.

Avalere analysis of Medicare fee-for-service (FFS) hospital stay claims with associated COVID-19 diagnoses finds that total US healthcare system costs for hospitalizations due to COVID-19 could range from $9.6B to $16.9B in 2020.

Recent Avalere analysis finds decreases in utilization of oncology and autoimmune treatments across all care settings since the onset of the health crisis.